NEW YORK, NY / ACCESSWIRE / August 2, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

TDOC Shareholders Click Here: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-submission-form?prid=30495&wire=1
WFC Shareholders Click Here: https://www.zlk.com/pslra-1/wells-fargo-lawsuit-loss-submission-form?prid=30495&wire=1
MOLN Shareholders Click Here: https://www.zlk.com/pslra-1/molecular-partners-class-action-loss-submission-form?prid=30495&wire=1

* ADDITIONAL INFORMATION BELOW *

Teladoc Health, Inc. (NYSE:TDOC)

TDOC Lawsuit on behalf of: investors who purchased October 28, 2021 - April 27, 2022
Lead Plaintiff Deadline : August 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-submission-form?prid=30495&wire=1

According to the filed complaint, during the class period, Teladoc Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) increased competition, among other factors, was negatively impacting Teladoc's BetterHelp and chronic care businesses; (ii) accordingly, the growth of those businesses was less sustainable than Defendants had led investors to believe; (iii) as a result, Teladoc's revenue and adjusted EBITDA projections for FY 2022 were unrealistic; (iv) as a result of all the foregoing, Teladoc would be forced to recognize a significant non-cash goodwill impairment charge; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Wells Fargo & Company (NYSE:WFC)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Wells Fargo common stock between February 24, 2021 and June 9, 2022.
Lead Plaintiff Deadline : August 29, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/wells-fargo-lawsuit-loss-submission-form?prid=30495&wire=1

According to the filed complaint, (i) Wells Fargo had misrepresented its commitment to diversity in the Company's workplace; (ii) Wells Fargo conducted fake job interviews in order to meet its Diverse Search Requirement; (iii) the foregoing conduct subjected Wells Fargo to an increased risk of regulatory and/or governmental scrutiny and enforcement action, including criminal charges; (iv) all of the foregoing, once revealed, was likely to negatively impact Wells Fargo's reputation; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Molecular Partners AG (NASDAQ:MOLN)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.
Lead Plaintiff Deadline : September 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/molecular-partners-class-action-loss-submission-form?prid=30495&wire=1

According to the filed complaint, (i) the Company's product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration ('FDA') was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization ('EUA'); (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) another of the Company's product candidates, MP0310, was less attractive to Molecular Partners' collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP